Masato Tobinai

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis

Toshitaka Nakamura, Tetsuo Nakano, Masako Ito et al. · Calcified Tissue International · 2013 · 58 citations · Full text

Medicine, Orthopedic Surgery, Bone Augmentation +16

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

Hiroshi Hagino, Seitaro Yoshida, Junko Hashimoto et al. · Calcified Tissue International · 2014 · 20 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study

Masako Ito, Masato Tobinai, Seitaro Yoshida et al. · Journal of Bone and Mineral Metabolism · 2015 · 15 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +13

Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study

Tetsuo Nakano, Masao Yamamoto, Junko Hashimoto et al. · Journal of Bone and Mineral Metabolism · 2015 · 10 citations

Medicine, Endocrinology, Bone Metabolism +14